CN112430643A - MiRNA multi-site joint detection method based on isothermal amplification - Google Patents
MiRNA multi-site joint detection method based on isothermal amplification Download PDFInfo
- Publication number
- CN112430643A CN112430643A CN202011405012.4A CN202011405012A CN112430643A CN 112430643 A CN112430643 A CN 112430643A CN 202011405012 A CN202011405012 A CN 202011405012A CN 112430643 A CN112430643 A CN 112430643A
- Authority
- CN
- China
- Prior art keywords
- mirna
- isothermal amplification
- site
- product
- universal primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091070501 miRNA Proteins 0.000 title claims abstract description 54
- 238000001514 detection method Methods 0.000 title claims abstract description 39
- 238000011901 isothermal amplification Methods 0.000 title claims abstract description 27
- 239000002679 microRNA Substances 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000000523 sample Substances 0.000 claims abstract description 23
- 108020004414 DNA Proteins 0.000 claims abstract description 12
- 239000011324 bead Substances 0.000 claims abstract description 9
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 9
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 8
- 239000012634 fragment Substances 0.000 claims abstract description 7
- 238000001215 fluorescent labelling Methods 0.000 claims abstract description 5
- 102000053602 DNA Human genes 0.000 claims abstract description 4
- 239000003298 DNA probe Substances 0.000 claims abstract description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 claims abstract description 4
- 108010090804 Streptavidin Proteins 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 238000009396 hybridization Methods 0.000 claims description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- 230000026731 phosphorylation Effects 0.000 claims description 8
- 238000006366 phosphorylation reaction Methods 0.000 claims description 8
- 102000003960 Ligases Human genes 0.000 claims description 7
- 108090000364 Ligases Proteins 0.000 claims description 7
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 102000012410 DNA Ligases Human genes 0.000 claims description 4
- 108010061982 DNA Ligases Proteins 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 101710086015 RNA ligase Proteins 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 238000010839 reverse transcription Methods 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 108091070511 Homo sapiens let-7c stem-loop Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 108091070521 Homo sapiens let-7a-1 stem-loop Proteins 0.000 description 4
- 108091070522 Homo sapiens let-7a-2 stem-loop Proteins 0.000 description 4
- 108091070513 Homo sapiens let-7a-3 stem-loop Proteins 0.000 description 4
- 108091070514 Homo sapiens let-7b stem-loop Proteins 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000007837 multiplex assay Methods 0.000 description 3
- 108091068840 Homo sapiens miR-101-1 stem-loop Proteins 0.000 description 2
- 108091065458 Homo sapiens miR-101-2 stem-loop Proteins 0.000 description 2
- 108091068943 Homo sapiens miR-105-1 stem-loop Proteins 0.000 description 2
- 108091068938 Homo sapiens miR-105-2 stem-loop Proteins 0.000 description 2
- 108091066023 Homo sapiens miR-200c stem-loop Proteins 0.000 description 2
- 108091067570 Homo sapiens miR-372 stem-loop Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000002512 suppressor factor Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a miRNA multi-site joint detection method based on isothermal amplification, which mainly comprises the following steps: 1) designing and synthesizing a specific single-stranded DNA probe aiming at each target miRNA sequence, and hybridizing the padlock probes with corresponding miRNA fragments to be detected to form a plurality of hybrid double strands; 2) connecting two ends of the padlock probe hybridized in the step 1); 3) performing rolling-circle isothermal amplification on the connection product obtained in the step 2); 4) hybridizing the product fragments obtained in the step 3) by using specific magnetic beads; 5) carrying out fluorescent labeling on the product obtained in the step 4) by using a streptavidin-labeled fluorescent dye; 6) detecting the fluorescent signal of the product in the step 5). The invention does not need reverse transcription, saves cost and reduces loss; the specificity is good, and single base can be distinguished; performing multiplex detection; the method can be applied to quantitative detection of multi-site miRNA in various fields, including but not limited to cancer screening, disease diagnosis, scientific research and the like.
Description
Technical Field
The invention belongs to the technical field of miRNA detection, and relates to an miRNA multi-site joint detection method based on isothermal amplification.
Background
microRNA (miRNA for short) is a small endogenous single-stranded RNA only containing 19-23 basic groups and widely exists in various eukaryotic cells. The abnormal expression of miRNA, as a highly conserved small molecule non-coding RNA, is involved in the process of various diseases, including multiple processes of cancer occurrence, development, metastasis, recurrence and the like, and the miRNA plays the role of carcinogenic factors or cancer suppressor factors according to different regulated genes, and the change of the expression level can be used as a marker for disease diagnosis and prognosis.
mirnas are very stable, quantifiable in a variety of bodily fluids, and their levels and composition in bodily fluids also have relevance to the situation of disease progression. In the field of non-invasive liquid biopsy, mirnas may serve as ideal candidate biomarkers for almost all human diseases, including cancer. In fact, miRNA has been added as a hematological molecular marker for liver cancer in primary liver cancer diagnosis and treatment specifications (2019). The standard indicates that the liver cancer detection kit based on the circulating miRNA model is verified by multiple hospitals at present, and three types of medical instrument registration certificates of the national drug supervision and administration are obtained, so that the liver cancer detection kit enters clinical application.
Currently, common miRNA detection methods are classified into two categories, direct detection and indirect detection. The direct detection method is mainly based on methods such as fluorescence, colorimetry, electrochemistry and the like, can directly detect the level and expression of miRNA, but has low sensitivity and is difficult to distinguish homologous miRNA with similar sequences. The indirect detection method mainly comprises Northern Blot, microarray chip, real-time fluorescent quantitative PCR (qRT-PCR) and other detection methods. Among them, Northern Blot and microarray chip methods are semi-quantitative methods, and have poor sensitivity and large demand for initial miRNA amount. In contrast, qRT-PCR is currently the most sensitive and efficient method for quantitatively detecting RNA.
The real-time qRT-PCR detection method based on the TaqMan probe is applied to the detection of miRNA, and the current market dominates the real-time fluorescent quantitative PCR method (TaqMan microRNA detection method) developed by Invitrogen (original ABI). According to the method, miRNA is subjected to reverse transcription through a stem-loop primer designed aiming at specific miRNA, and then fluorescence quantification is performed by using a TaqMan probe and a specific primer. Although the method overcomes the defects of most miRNA detection methods to a certain extent, the method has the following problems. First, although the detection sensitivity of the TaqMan probe is high, the design of each miRNA is not only cost-prohibitive, but also technically challenging. Secondly, the method cannot perform multiple detection of miRNA in the same reaction hole, and the detection of single miRNA locus has relatively low sensitivity and specificity for disease diagnosis. Together with the high detection cost of the method, the defects limit the wide application and clinical transformation of the method.
Disclosure of Invention
In view of the above problems, the present invention aims to provide a miRNA multi-site combined detection method based on isothermal amplification.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a miRNA multi-site joint detection method based on isothermal amplification, which comprises the following steps:
1) designing and synthesizing an upstream universal primer and a downstream universal primer with biotin labels at the 5' ends; designing and synthesizing a specific single-stranded DNA probe aiming at each target miRNA sequence, and hybridizing the padlock probes with corresponding miRNA fragments to be detected to form a plurality of hybrid double strands;
the probes are as follows from the 5' end: phosphorylation marker-8-14 base reverse complementary sequence of 5 'end of miRNA-specific tag sequence-downstream universal primer reverse complementary sequence-upstream universal primer sequence-residual base reverse complementary sequence of 3' end of miRNA;
2) ligating two ends of the padlock probe hybridized successfully in the step 1) by using ligase;
3) performing rolling-circle isothermal amplification on the ligation product in the step 2) by using an upstream universal primer and a downstream universal primer;
4) hybridizing the product fragments obtained in the step 3) by using specific magnetic beads;
5) carrying out fluorescent labeling on the product obtained in the step 4) by using a streptavidin-labeled fluorescent dye;
6) detecting the fluorescent signal of the product in the step 5).
Preferably, in step 1), the hybridization conditions are: slowly cooling to room temperature at 80-90 deg.C for 2-5min, and maintaining for 2-4 h.
Preferably, in step 2), the ligase is selected from T4 DNA ligase or T4 RNA ligase or splntr DNA ligase.
Preferably, in step 2), the connection conditions are: 16-37 deg.C, 15-60 min.
Preferably, in step 3), the amplification reaction may be any commercially available isothermal amplification reaction kit.
Preferably, in step 3), the isothermal amplification reaction conditions are 20-40 ℃ for 2-12 h.
Preferably, in step 4), the specific magnetic beads are coupled with specific nucleic acid sequences, and each microsphere is provided with a different label capable of binding to a specific PCR product.
Preferably, in step 4), the hybridization reaction conditions are: 85-100 ℃ for 60-120 s; 25-40 deg.C, 10-20 min.
Preferably, in step 5), the reaction conditions for carrying out the fluorescent labeling are: 25-37 deg.C, 10-30 min.
Compared with the prior art, the invention has the following advantages:
1. reverse transcription is not needed, so that the cost is saved, and the loss is reduced;
2. the specificity is good, and single bases can be distinguished (see example 1);
3. multiplex assays (see example 2);
4. the method provided by the invention can be applied to quantitative detection of the multi-site miRNA in various fields, including but not limited to cancer screening, disease diagnosis, scientific research and the like.
Drawings
FIG. 1 is a schematic flow chart of the combined detection method of multiple miRNA sites.
FIG. 2 shows the results of the specific detection of hsa-let-7c-5p in example 1 of the present invention.
FIG. 3 shows the result of the multiplex detection of breast cancer samples in example 2 of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the following examples of the present invention,
ligase and 10 Xligase buffer with Thermo ScientificTM T4 DNA Ligase，EL0011；
The formula of the hybridization solution is as follows: 0.4M NaCl, 0.2M Tris, 0.016% Triton X-100, pH 8.0, stored at 4 ℃;
the magnetic beads adopt MagPlex-TAG Microspheres,
the formula of the color reaction liquid is as follows: add 1. mu.l of SAPE to every 80. mu.l of hybridization solution, manufacturer: moss SAPE-001G75, Life
S-886。
Unless otherwise specified, each step in the examples can be realized by using materials and conventional technical means in the field.
Example 1 assay for detection specificity
First, primer and probe design principle
1. Designing two universal primers (a primer F and a primer R), wherein the two universal primers are non-human sequences and are not communicated with known human DNA and RNA sequences or are similar to more than 4 continuous bases through sequence comparison; the 5' end of the universal primer F is provided with a biotin label.
2. The length of the universal primer sequence is 18-25bp, and the Tm value is 55-65 ℃.
3. According to a miRNA sequence to be detected, 1 specific single-stranded DNA probe is designed according to the following principle:
1) the length is 80-100 nt;
2) the nucleic acid sequence is a reverse complementary sequence of 8-14 bases from the 5 ' end to the 3 ' end of the miRNA, a specific tag sequence C, a reverse complementary sequence of a universal primer R, a sequence of a universal primer F and a sequence reverse complementary to all the remaining bases at the 3 ' end of the miRNA in sequence from the 5 ' end to the 3 ' end;
3) the 5' end of the probe is modified by phosphorylation.
Second, Hsa-let-7c-5p specificity analysis
1. And (3) synthesizing a standard substance, and designing and synthesizing a primer and a probe according to the method in the step one.
1) The universal primers were synthesized with the following sequences:
a universal primer F: biotin-CCAGATAAGGGTGTTATG (SEQ ID NO: 1), wherein biotin represents a biotin modification;
a universal primer R: GAATGGGCGGATTGCCT (SEQ ID NO: 2).
2) Synthesizing hsa-let-7a-5p, hsa-let-7b-5p and hsa-let-7c-5p standard products, wherein the sequences are as follows:
hsa-let-7a-5p:UGAGGUAGUAGGUUGUAUAGUU(SEQ ID NO：3)
hsa-let-7b-5p:UGAGGUAGUAGGUUGUGUGGUU(SEQ ID NO：4)
hsa-let-7c-5p:UGAGGUAGUAGGUUGUAUGGUU(SEQ ID NO：5)。
3) the probe of hsa-let-7c-5p is synthesized, and the sequence is as follows:
hsa-let-7c-5p-L：
P-CTACTACCTCACAATTTACATTTCACTTTCTTATCAGGCAATCCGCCCATTCagcgagtcaaCCAGATAAGGGTGTTATGAACCATACAAC (SEQ ID NO: 6), wherein P represents a phosphorylation modification.
MiRNA detection
Adding the dry powder of the standard substance of hsa-let-7a-5p, hsa-let-7b-5p and hsa-let-7c-5p into the non-enzyme water respectively for dissolving, and diluting to 1015Copy/ml, 10-fold gradient dilution standard, 10 of each10Copies/ml were used as standard templates and three samples were tested separately using hsa-let-7c-5 p-L.
The detection is carried out according to the following steps:
1) 1. mu.l of the above template was taken, and added to the reaction: 1 ul of probe hsa-let-7c-5p-L, 1 ul of 10 Xligase buffer, and supplementing water to 10 ul;
2) the reaction system carries out hybridization reaction in a PCR instrument, and the procedure is as follows: slowly cooling to 22 deg.C for 2min at 85 deg.C, and maintaining for 2 hr;
3) taking 2 ul of the product, adding 1 ul of ligase and 2 ul of 10 Xligase buffer, and replenishing water to 20 ul;
4) the reaction system carries out a connection reaction in a PCR instrument, and the procedure is as follows: 30min at 25 ℃ and 10min at 65 ℃;
5) taking 20 mul of product, adding 0.5 mul of isothermal amplification enzyme, 5 mul of 10 multiplied by isothermal amplification enzyme buffer, 2 mul of universal primer F and 2 mul of universal primer R, and supplementing water to 50 mul;
6) the reaction system carries out isothermal amplification reaction in a PCR instrument, and the procedure is as follows: 6h at 37 ℃ and 10min at 65 ℃;
7) add 10. mu.l of product, 30. mu.l of hybridization solution, 3. mu.l of magnetic beads to 96-well plate, add water to 50. mu.l, seal membrane, and perform reaction in PCR instrument with the following procedure: at 90 ℃ for 80 s; at 37 ℃ for 20 min;
8) after the hybridization reaction is finished, the 96-well plate is placed on a magnetic frame for 2min, the supernatant is removed by suction, 25 mul of chromogenic reaction liquid is added, the membrane is sealed, the reaction is carried out in a PCR instrument, and the procedure is as follows: at 37 ℃ for 10 min;
9) after the color reaction is finished, the PCR reaction product is taken down from the PCR instrument and is immediately placed on a magnetic plate to stand for 60s, and the supernatant is discarded. Adding 50 μ l of hybridization solution (the same hybridization solution as in step 7), shaking and mixing for 20-30s, standing on magnetic plate for 60s, discarding supernatant, and repeating for 1 time. Adding 75 μ l of the hybridization solution, shaking and mixing for 30 s;
10) the luminex 200 was used for on-machine testing.
3. The experimental results are shown in FIG. 2, NC is a negative control, the result of hsa-let-7c-5p is 3 times greater than that of NC, and the results of hsa-let-7a-5p and hsa-let-7b-5p are both 3 times less than that of NC, thus proving that the probe hsa-let-7c-5p-L can specifically detect hsa-let-7c-5p, but cannot detect fragments with only 1 base difference, and proving that the specificity of the method is better.
Example 2 multiplex assay
1. Extracting miRNA from the plasma sample:
miRNA extraction was performed on 5 breast cancer patients and 5 healthy control plasma (plasma samples of healthy persons and patients from cooperative hospitals, signed with written consent and sequence verified) using a serum/plasma miRNA extraction and isolation kit (DP503) produced by tiangen biochemistry technology (beijing) ltd according to the instruction method.
2. The probe design and synthesis were performed according to the method described in example 1.
Synthesizing hsa-miR-200c-3p, hsa-miR-101-3p, hsa-miR-372-3p and hsa-miR-105-5p standard products, wherein the sequences are as follows:
hsa-miR-200c-3p:UAAUACUGCCGGGUAAUGAUGGA(SEQ ID NO：7)
hsa-miR-101-3p:UACAGUACUGUGAUAACUGAA(SEQ ID NO：8)
hsa-miR-372-3p:AAAGUGCUGCGACAUUUGAGCGU(SEQ ID NO：9)
hsa-miR-105-5p:UAACACUGUCUGGUAAAGAUGG(SEQ ID NO：10)
probes were designed and synthesized with the following sequences:
hsa-miR-200c-3p-L：
P-CCGGCAGTATTAACAAATATCTAACTACTATCACAATCACAATCCGCCCATTCagcgagtcaaCCAGATAAGGGTGTTGCGTCCATCATTAC (SEQ ID NO: 11), wherein P represents a phosphorylation modification;
hsa-miR-101-3p-L：
P-ACAGTACTGTACAATTTACATTTCACTTTCTTATCTCACAATCCGCCCATTCagcgagtcaaCCAGATAAGGGTGTTGCGTTCAGTTATC (SEQ ID NO: 12), wherein P represents a phosphorylation modification;
hsa-miR-372-3p-L：
P-GTCGCAGCACTTTTTAACAACTTATACAAACACAAACTCACAATCCGCCCATTCagcgagtcaaCCAGATAAGGGTGTTGCGACGCTCAAAT (SEQ ID NO: 13), wherein P represents a phosphorylation modification;
hsa-miR-105-5p-L：
P-CTGAGCATTTGAACATCAAATTCTTTCAATATCTTCTCACAATCCGCCCATTCagcgagtcaaCCAGATAAGGGTGTTGCGACCACAGGAGT (SEQ ID NO: 14), wherein P represents a phosphorylation modification.
3. Multiplex assays
Dissolving various standard dry powders in non-enzyme water respectively, and then adding the mixture into the mixture according to the proportion of 1: 1 proportion and diluted to 1014Copy/ml, following the procedure in example 2, a gradient dilution of each standard was prepared separately. The concentration of each component after dilution is 1010Copy/ml standard and extracted miRNA in breast cancer patient/healthy human plasma sampleAs a template, all probes were mixed at the same concentration to serve as a multiplex detection probe, and detection was performed according to the following procedure:
1) taking 10 ul of the template, adding the following components into the reaction system: mu.l probe, 2. mu.l 10 Xligase buffer, and water to 20. mu.l;
2) the reaction system carries out hybridization reaction in a PCR instrument, and the procedure is as follows: slowly cooling to 22 deg.C for 2min at 85 deg.C, and maintaining for 2 hr;
3) taking 10 ul of the product, adding 1 ul of ligase and 2 ul of 10 Xligase buffer, and replenishing water to 20 ul;
4) the reaction system carries out a connection reaction in a PCR instrument, and the procedure is as follows: 30min at 25 ℃ and 10min at 65 ℃;
5) adding 0.5. mu.l of isothermal amplification enzyme, 5. mu.l of 10 Xisothermal amplification enzyme buffer, 3. mu.l of primer F and 3. mu.l of primer R into 20. mu.l of product, and replenishing water to 50. mu.l;
6) the reaction system carries out isothermal amplification reaction in a PCR instrument, and the procedure is as follows: 6h at 37 ℃ and 10min at 65 ℃;
7) add 10. mu.l of product, 30. mu.l of hybridization solution, 3. mu.l of magnetic beads to 96-well plate, add water to 50. mu.l, seal membrane, and perform reaction in PCR instrument with the following procedure: at 90 ℃ for 80 s; at 37 ℃ for 20 min;
8) after the hybridization reaction is finished, the 96-well plate is placed on a magnetic frame for 2min, the supernatant is removed by suction, 25 mul of chromogenic reaction liquid is added, the membrane is sealed, the reaction is carried out in a PCR instrument, and the procedure is as follows: at 37 ℃ for 10 min;
9) after the color reaction is finished, the PCR reaction product is taken down from the PCR instrument and is immediately placed on a magnetic plate to stand for 60s, and the supernatant is discarded. Adding 50 μ l of hybridization solution, shaking and mixing for 20-30s, standing on magnetic plate for 60s, discarding supernatant, and repeating for 1 time. Adding 75 μ l of the hybridization solution, shaking and mixing for 30 s;
10) the luminex 200 was used for on-machine testing.
4. The experimental results are shown in FIG. 3, NC is negative control, PC is positive control, and the detection results of several sites of the positive control are all more than 3 times of the corresponding value N, which proves that the method can simultaneously detect a plurality of sites; at least 2 sites of all 5 patient samples are positive, and all the healthy controls are positive, the results are less than 2, so that the method is proved to be capable of well distinguishing breast cancer samples.
Sequence listing
<110> Oncai Life technologies (Suzhou) Ltd
<120> miRNA multi-site joint detection method based on isothermal amplification
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 18
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
ccagataagg gtgttatg 18
<210> 2
<211> 17
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
gaatgggcgg attgcct 17
<210> 3
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
ugagguagua gguuguauag uu 22
<210> 4
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
ugagguagua gguugugugg uu 22
<210> 5
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ugagguagua gguuguaugg uu 22
<210> 6
<211> 91
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
ctactacctc acaatttaca tttcactttc ttatcaggca atccgcccat tcagcgagtc 60
aaccagataa gggtgttatg aaccatacaa c 91
<210> 7
<211> 23
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
uaauacugcc ggguaaugau gga 23
<210> 8
<211> 21
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
uacaguacug ugauaacuga a 21
<210> 9
<211> 23
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
aaagugcugc gacauuugag cgu 23
<210> 10
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
uaacacuguc ugguaaagau gg 22
<210> 11
<211> 92
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
ccggcagtat taacaaatat ctaactacta tcacaatcac aatccgccca ttcagcgagt 60
caaccagata agggtgttgc gtccatcatt ac 92
<210> 12
<211> 90
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
acagtactgt acaatttaca tttcactttc ttatctcaca atccgcccat tcagcgagtc 60
aaccagataa gggtgttgcg ttcagttatc 90
<210> 13
<211> 92
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
gtcgcagcac tttttaacaa cttatacaaa cacaaactca caatccgccc attcagcgag 60
tcaaccagat aagggtgttg cgacgctcaa at 92
<210> 14
<211> 92
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
ctgagcattt gaacatcaaa ttctttcaat atcttctcac aatccgccca ttcagcgagt 60
caaccagata agggtgttgc gaccacagga gt 92
Claims (8)
1. An isothermal amplification-based miRNA multi-site combined detection method comprises the following steps:
1) designing and synthesizing an upstream universal primer and a downstream universal primer with biotin labels at the 5' ends; designing and synthesizing a specific single-stranded DNA probe aiming at each target miRNA sequence, and hybridizing the padlock probes with corresponding miRNA fragments to be detected to form a plurality of hybrid double strands;
the probes are as follows from the 5' end: phosphorylation marker-8-14 base reverse complementary sequence of 5 'end of miRNA-specific tag sequence-downstream universal primer reverse complementary sequence-upstream universal primer sequence-residual base reverse complementary sequence of 3' end of miRNA;
2) ligating two ends of the padlock probe hybridized successfully in the step 1) by using ligase;
3) performing rolling-circle isothermal amplification on the ligation product in the step 2) by using an upstream universal primer and a downstream universal primer;
4) hybridizing the product fragments obtained in the step 3) by using specific magnetic beads;
5) carrying out fluorescent labeling on the product obtained in the step 4) by using a streptavidin-labeled fluorescent dye;
6) detecting the fluorescent signal of the product in the step 5).
2. The miRNA multi-site joint detection method based on isothermal amplification according to claim 1, wherein in the step 1), the hybridization conditions are as follows: slowly cooling to room temperature at 80-90 deg.C for 2-5min, and maintaining for 2-4 h.
3. The method for detecting miRNA multi-site combination based on isothermal amplification of claim 1, wherein in step 2), the ligase is selected from T4 DNA ligase, T4 RNA ligase or SplintRNAligase.
4. The method for detecting miRNA multi-site combination based on isothermal amplification according to claim 1 or 3, wherein in step 2), the connection conditions are as follows: 16-37 deg.C, 15-60 min.
5. The miRNA multi-site joint detection method based on isothermal amplification according to claim 1, wherein in the step 3), the isothermal amplification reaction conditions are 20-40 ℃ and 2-12 h.
6. The method as claimed in claim 1, wherein in step 4), the specific magnetic beads are coupled with specific nucleic acid sequences, and each microsphere has a different label, so that the specific beads can bind to a specific PCR product.
7. The method for detecting miRNA multi-site combination based on isothermal amplification according to claim 1 or 6, wherein in step 4), the hybridization reaction conditions are as follows: 85-100 ℃ for 60-120 s; 25-40 deg.C, 10-20 min.
8. The miRNA multi-site combined detection method based on isothermal amplification according to claim 1, wherein in the step 5), the reaction conditions for fluorescence labeling are as follows: 25-37 deg.C, 10-30 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011405012.4A CN112430643A (en) | 2020-12-03 | 2020-12-03 | MiRNA multi-site joint detection method based on isothermal amplification |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011405012.4A CN112430643A (en) | 2020-12-03 | 2020-12-03 | MiRNA multi-site joint detection method based on isothermal amplification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112430643A true CN112430643A (en) | 2021-03-02 |
Family
ID=74692252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011405012.4A Pending CN112430643A (en) | 2020-12-03 | 2020-12-03 | MiRNA multi-site joint detection method based on isothermal amplification |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112430643A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114622009A (en) * | 2022-02-28 | 2022-06-14 | 广州天源高新科技有限公司 | miRNA molecular marker for early diagnosis of gestational diabetes and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102676642A (en) * | 2011-03-17 | 2012-09-19 | 姬云 | Multi-target-point quantitative nucleic acid detection method based on liquid phase chip |
| CN102827929A (en) * | 2012-08-01 | 2012-12-19 | 浙江大学 | Method for detecting nucleic acid |
| CN103525932A (en) * | 2013-10-17 | 2014-01-22 | 中国人民解放军第三军医大学第三附属医院 | Hyper-branched rolling cycle amplification detection method for micro ribonucleic acid (RNA) |
| CN104017861A (en) * | 2014-04-23 | 2014-09-03 | 常州方圆制药有限公司 | Nucleic acid detection method |
| CN106834508A (en) * | 2017-03-17 | 2017-06-13 | 武汉大学 | The method that the hyper-branched rolling circle amplification that a kind of coupled reaction triggers detects miRNA |
| CN108265109A (en) * | 2018-04-08 | 2018-07-10 | 武汉大学 | The B-RCA methods and kit of the low abundance miR-33a/b of a kind of clinical detection |
| CN111635931A (en) * | 2020-05-27 | 2020-09-08 | 北京理工大学 | Multi-target miRNA detection micro-fluidic chip, detection method and rapid quantitative detection system thereof |
-
2020
- 2020-12-03 CN CN202011405012.4A patent/CN112430643A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102676642A (en) * | 2011-03-17 | 2012-09-19 | 姬云 | Multi-target-point quantitative nucleic acid detection method based on liquid phase chip |
| CN102827929A (en) * | 2012-08-01 | 2012-12-19 | 浙江大学 | Method for detecting nucleic acid |
| CN103525932A (en) * | 2013-10-17 | 2014-01-22 | 中国人民解放军第三军医大学第三附属医院 | Hyper-branched rolling cycle amplification detection method for micro ribonucleic acid (RNA) |
| CN104017861A (en) * | 2014-04-23 | 2014-09-03 | 常州方圆制药有限公司 | Nucleic acid detection method |
| CN106834508A (en) * | 2017-03-17 | 2017-06-13 | 武汉大学 | The method that the hyper-branched rolling circle amplification that a kind of coupled reaction triggers detects miRNA |
| CN108265109A (en) * | 2018-04-08 | 2018-07-10 | 武汉大学 | The B-RCA methods and kit of the low abundance miR-33a/b of a kind of clinical detection |
| CN111635931A (en) * | 2020-05-27 | 2020-09-08 | 北京理工大学 | Multi-target miRNA detection micro-fluidic chip, detection method and rapid quantitative detection system thereof |
Non-Patent Citations (5)
| Title |
|---|
| ENRICO CADONI等: "PNA-Based MicroRNA Detection Methodologies", 《MOLECULES》 * |
| GUILLAUME GINES等: "Emerging isothermal amplification technologies for microRNA biosensing: Applications to liquid biopsies", 《MOLECULAR ASPECTS OF MEDICINE》 * |
| NAM-IN GOO等: "Rolling Circle Amplification as Isothermal Gene Amplification in Molecular Diagnostics", 《B26IO2CHIP J.》 * |
| YUNFEI GUO等: "A noise-free, ultrasensitive and accurate miRNAs detection using streptavidin coated magnetic microsphere based stem-loop ligation PCR", 《TALANTA》 * |
| 成永强等: "滚环扩增阳离子共轭聚合物均相检测microRNA", 《河北大学学报(自然科学版)》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114622009A (en) * | 2022-02-28 | 2022-06-14 | 广州天源高新科技有限公司 | miRNA molecular marker for early diagnosis of gestational diabetes and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107002292B (en) | A kind of construction method and reagent in the twin adapter single stranded circle library of nucleic acid | |
| AU2011329753B2 (en) | ncRNA and uses thereof | |
| KR102006803B1 (en) | A Method for Multiple Detection of Methylated DNA | |
| US20230340590A1 (en) | Method for verifying bioassay samples | |
| CN109689896A (en) | Fetal chromosomal aneuploidy is detected using the region of DNA domain of the differential methylation between fetus and pregnant female animal | |
| JP6143041B2 (en) | Colon cancer test kit | |
| WO2011142836A9 (en) | Assays for the detection of genotype, mutations, and/or aneuploidy | |
| CN102046808A (en) | Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers | |
| CN112501255A (en) | Multi-site miRNA combined detection method | |
| WO2019144582A1 (en) | Probe and method for high-throughput sequencing targeted capture target region used for detecting gene mutations as well as known and unknown gene fusion types | |
| CN102002494B (en) | microRNA biomarker and application thereof | |
| CN109837275B (en) | Preparation method of fusion gene positive control standard substance | |
| WO2023025259A1 (en) | Method and kit for detecting microrna | |
| Hanson et al. | RNA profiling for the identification of the tissue origin of dried stains in forensic biology | |
| WO2020007089A1 (en) | Construction and sequencing data analysis method for ctdna library for simultaneously detecting various common mutations in liver cancer | |
| CN106757379A (en) | Lung cancer polygenic variation library constructing method | |
| CN109563540A (en) | DNA probe in situ hybridization on chromosome | |
| CN111979307A (en) | Targeted sequencing method for detecting gene fusion | |
| CN112430643A (en) | MiRNA multi-site joint detection method based on isothermal amplification | |
| CN105506156A (en) | Molecular marker for diagnosing osteosarcoma | |
| CN105441565A (en) | miRNA regarding as osteosarcoma treatment target | |
| Faragó et al. | Purification of high-quality micro RNA from the heart tissue | |
| CN110452958B (en) | Joint, primer and kit for methylation detection of micro-fragmented nucleic acid and application of joint and primer and kit | |
| CN107513570A (en) | The method and kit of more target library constructions are uniformed based on high-flux sequence | |
| KR20220077907A (en) | Library building method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210302 |